7 Most Undervalued Biotech Stocks To Invest In
On February 21, Jared Holz, Mizuho Securities America's healthcare sector strategist, appeared on CNBC to discuss Trump's tariffs and their effects on the American pharma sector.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 5,329,743 | $492,308,361 | +28% | 0.72% |
| 2. | Citadel Investment Group Ken Griffin | 4,695,889 | $433,759,267 | -7% | 0.07% |
| 3. | AQR Capital Management Cliff Asness | 1,813,554 | $167,517,983 | -7% | 0.21% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 1,714,130 | $158,334,188 | 0.27% | |
| 5. | 1,387,200 | $128,135,664 | +17% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | Director | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | Director | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | Director | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | Director | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | Director | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $110.53 | 2,500 | Officer | 170,674 | 2025-03-17 | Filing | |
| $118.50 | 13,013 | Officer | 169,061 | 2025-03-10 | Filing | |
| $117.30 | 4,916 | Officer | 182,074 | 2025-03-10 | Filing | |
| $104.09 | 2,500 | Officer | 169,061 | 2025-02-18 | Filing | |
| $102.22 | 137,676 | Officer | 171,223 | 2025-02-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 120,355,841 | $11,117,269,080 | 0.22% | |
| 2. | 115,528,392 | $10,671,357,569 | 0.18% | |
| 3. | 71,706,362 | $6,623,424,305 | 1% | |
| 4. | 60,381,755 | $5,577,339,316 | 0.22% | |
| 5. | 57,946,228 | $5,352,490,497 | 1.1% |
News See All
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds
The NASDAQ Index closed more than 10% below its December high of 20,174 on March 6, 2025. This officially puts the index in a market correction – which has happened a dozen times since 2010.
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Top 10 Stocks Wall Street is Discussing
Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market rally that started during the peak of the pandemic driven by fiscal stimulus seems to have...
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.
10 Stocks That Analysts Think Will Go Up
The S&P 500 index touched an all-time high this week as Mark Zuckerberg’s company's 20-day streak finally came to an end, adding $320 billion to the company’s market cap.
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. (GILD) on Substack by Disruptive analytics. In this article, we will summarize the bulls’ thesis on GILD. Gilead Sciences, Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year 2024 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Why Gilead (GILD) Is Advancing Today
Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts' average estimate...